SARS-CoV-2 Main Protease (Mpro) in Complex with ML1001

SARS-CoV-2 Main Protease (Mpro) in Complex with ML1001 Descriptor: (1R,2S,5S)-N-{(2S,3R)-4-amino-3-hydroxy-4-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl}-3-[N-(3,3-dimethylbutanoyl)-3-methyl-L-valyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, 3C-like proteinase Authors: Westberg, M, Fernandez, D, Lin, M.Z. Deposit date: 2021-10-02 Release date: 2022-10-05 Last modified: 2024-11-13 Method: X-RAY DIFFRACTION (1.85 Å) Cite: An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations. Sci Transl Med, 16, 2024